Literature DB >> 18451140

Transforming growth factor beta induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells.

Jing Wang1, Limin Yang, Junhua Yang, Karen Kuropatwinski, Wang Wang, Xiao-Qiong Liu, Jennie Hauser, Michael G Brattain.   

Abstract

FET cells, derived from an early-stage colon carcinoma, are nontumorigenic in athymic mice. Stable transfection of a dominant-negative transforming growth factor beta (TGFbeta) type II receptor (DNRII) into FET cells that express autocrine TGFbeta shows loss of TGFbeta signaling and increased tumorigenicity in vivo indicating tumor suppressor activity of TGFbeta signaling in this model. The ability of tumorigenic cells to withstand growth factor and nutrient deprivation stress (GFDS) is widely regarded as a key attribute for tumor formation and progression. We hypothesized that increased tumorigenicity of FET/DNRII cells was due to loss of participation of autocrine TGFbeta in a "fail-safe" mechanism to generate cell death in response to this stress. Here, we document that loss of autocrine TGFbeta in FET/DNRII cells resulted in greater endogenous cell survival in response to GFDS due to activation of the phosphoinositide 3-kinase (PI3K)/Akt/survivin pathway. Treatment of FET DNRII cells with a PI3K inhibitor (LY294002) inhibited Akt phosphorylation and reduced survivin expression resulting in increased apoptosis in FET/DNRII cells. We also show that exogenous TGFbeta increased apoptosis in FET cells through repression of the PI3K/Akt/survivin pathway during GFDS. These results indicate that the PI3K/Akt/survivin pathway is blocked by TGFbeta signaling and that loss of autocrine TGFbeta leads to increased cell survival during GFDS through the novel linkage of TGFbeta-mediated repression of survivin expression. Inhibition of survivin function by dominant-negative approaches showed that this inhibitor of apoptosis family member is critical to cell survival in the FET/DNRII cells, thus indicating the importance of this target for TGFbeta-mediated apoptosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18451140     DOI: 10.1158/0008-5472.CAN-07-5348

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

1.  Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer.

Authors:  Moubin Lin; David J Stewart; Margaret R Spitz; Michelle A T Hildebrandt; Charles Lu; Jie Lin; Jian Gu; Maosheng Huang; Scott M Lippman; Xifeng Wu
Journal:  Carcinogenesis       Date:  2011-04-22       Impact factor: 4.944

2.  Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death.

Authors:  Sanjib Chowdhury; Gillian M Howell; Carol A Teggart; Aparajita Chowdhury; Jonathan J Person; Dawn M Bowers; Michael G Brattain
Journal:  J Biol Chem       Date:  2011-07-08       Impact factor: 5.157

3.  Cytoplasmic localization of wild-type survivin is associated with constitutive activation of the PI3K/Akt signaling pathway and represents a favorable prognostic factor in patients with acute myeloid leukemia.

Authors:  Juana Serrano-López; Josefina Serrano; Vianihuini Figueroa; Antonio Torres-Gomez; Salvador Tabares; Javier Casaño; Noemi Fernandez-Escalada; Joaquín Sánchez-Garcia
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

Review 4.  TGFβ signaling in head and neck squamous cell carcinoma.

Authors:  R A White; S P Malkoski; X-J Wang
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

5.  Ezrin expression and cell survival regulation in colorectal cancer.

Authors:  Premila D Leiphrakpam; Ashwani Rajput; Michelle Mathiesen; Ekta Agarwal; Audrey J Lazenby; Chandrakanth Are; Michael G Brattain; Sanjib Chowdhury
Journal:  Cell Signal       Date:  2014-01-22       Impact factor: 4.315

6.  Transgenic expression of survivin compensates for OX40-deficiency in driving Th2 development and allergic inflammation.

Authors:  Fengyang Lei; Jianyong Song; Rizwanul Haque; Xiaofang Xiong; Deyu Fang; Yuzhang Wu; Susanne M A Lens; Michael Croft; Jianxun Song
Journal:  Eur J Immunol       Date:  2013-05-28       Impact factor: 5.532

7.  Impaired insulin-mediated vasorelaxation in diabetic Goto-Kakizaki rats is caused by impaired Akt phosphorylation.

Authors:  Jin Hee Lee; Thomas Palaia; Louis Ragolia
Journal:  Am J Physiol Cell Physiol       Date:  2008-12-03       Impact factor: 4.249

8.  Rewiring of the apoptotic TGF-β-SMAD/NFκB pathway through an oncogenic function of p27 in human papillary thyroid cancer.

Authors:  A R Garcia-Rendueles; J S Rodrigues; M E R Garcia-Rendueles; M Suarez-Fariña; S Perez-Romero; F Barreiro; I Bernabeu; J Rodriguez-Garcia; L Fugazzola; T Sakai; F Liu; J Cameselle-Teijeiro; S B Bravo; C V Alvarez
Journal:  Oncogene       Date:  2016-07-25       Impact factor: 9.867

9.  A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy.

Authors:  Yoshitaka Nakamura; Shingo Yogosawa; Yasuyuki Izutani; Hirotsuna Watanabe; Eigo Otsuji; Tosiyuki Sakai
Journal:  Mol Cancer       Date:  2009-11-12       Impact factor: 27.401

10.  Analysis of newly established EST databases reveals similarities between heart regeneration in newt and fish.

Authors:  Thilo Borchardt; Mario Looso; Marc Bruckskotten; Patrick Weis; Julia Kruse; Thomas Braun
Journal:  BMC Genomics       Date:  2010-01-04       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.